Suven Pharmaceuticals Ltd

Cohance Lifesciences Ltd has announced that its Board of Directors will convene on November 6, 2026. The primary agenda item is the consideration and approval of the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half-year ended September 30, 2026. The company also confirmed that the trading window, closed since September 28, 2026, for designated persons and their relatives, will remain shut until November 9, 2026.

Cohance Lifesciences Ltd has received approval from the Ministry of Corporate Affairs (Central Government) for the appointment of Mr. Umang Vohra (DIN: 02296740) as Chairman and Group CEO. This approval, communicated via a letter dated 8 October 2026 and received by the company on 12 October 2026, formalizes the appointment previously indicated in letters dated 27 April 2026 and 26 June 2026. This development signifies a key leadership confirmation for the company.

Cohance Lifesciences Ltd announced the grant of employee stock options (ESOPs) to eligible employees. The Nomination and Remuneration Committee approved the grant of 2,60,194 options under the ESOP 2026 plan and 6,14,594 options under the Suven Pharmaceuticals Limited – Employee Stock Option Plan 2023. The ESOP 2026 options have an exercise price not less than INR 325, with vesting between 1 to 8 years and exercise up to 3 years post-vesting. The ESOP 2023 options were granted at an exercise price of INR 495, with vesting between 1 to 10 years.

Cohance Lifesciences Ltd announced the appointment of Mr. Abhimanyu Ojha as its new Chief Financial Officer (CFO) and Key Managerial Personnel, effective October 12, 2026. The decision was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee. Mr. Ojha brings over two decades of experience in finance leadership roles within multinational healthcare and pharmaceutical companies, including Intas Pharmaceuticals, Viatris, Sun Pharmaceuticals, and Ranbaxy Laboratories. His expertise spans financial strategy, business partnering, corporate governance, M&A, and operational excellence. The company also updated its authorized Key Managerial Personnel list for regulatory disclosures.

Cohance Lifesciences Ltd has been voluntarily assigned an ESG Rating of "Crisil ESG 61 (Strong)" and a Core ESG Rating of "Crisil Core ESG 67 (Strong)" by Crisil ESG Ratings & Analytics Limited. The rating was independently determined by Crisil ESG Ratings based on publicly available information and the company did not engage Crisil for this assessment. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Cohance Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The exact date of the board meeting to approve these results will be communicated later. This measure is standard practice to prevent potential insider trading before the public release of financial information.

Cohance Lifesciences Ltd announced that its API manufacturing facility in Jaggaiahpet, Andhra Pradesh, was inspected by the United States Food and Drug Administration (USFDA) from September 14 to September 19, 2026. The inspection concluded with the issuance of a Form FDA 483, detailing five observations. The company has stated that it has initiated corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. Cohance Lifesciences reaffirmed its commitment to quality and regulatory compliance.

Cohance Lifesciences Ltd has completed a $10 million investment in its US-based subsidiary, NJ Bio Inc., through the subscription of Compulsorily Convertible Preferred Stock (CCPS). This funding is intended to support NJ Bio's growth initiatives, particularly in the Antibody Drug Conjugate (ADC) and broader 'XDC' space. NJ Bio operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities in ADC development. The transaction, classified as a related party transaction at arm's length, is expected to be completed by the end of September 2026. This strategic investment reinforces Cohance's commitment to the high-growth ADC sector.

Cohance Lifesciences Ltd has announced the completion of an inspection by the United States Food and Drug Administration (USFDA) at its formulation (FDF) plant in Shamshabad, Telangana. The inspection, which took place from August 27 to September 4, 2026, concluded with the issuance of a Form FDA 483, detailing four observations. The company has confirmed that it has initiated corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. Cohance Lifesciences reiterated its commitment to quality and regulatory compliance.

Cohance Lifesciences Limited announced two strategic transactions to bolster its Antibody-drug Conjugate (ADC) strategy, involving a USD 13 million investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio. These investments, funded by internal accruals, aim to deepen NJ Bio's integration with Cohance for customer-facing services and focus Aruka's proprietary pipeline development through partnerships. Cohance will increase its ownership in NJ Bio to 67.3% and gain a 65% direct ownership in Aruka Bio, which will become a direct subsidiary. These moves are expected to strengthen business performance and position Aruka's platform for future collaborations. Completion is anticipated by the end of September 2026.